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Abstract 
Life-threatening bleeding in anticoagula-
tion with Warfarin is an emergency challeng-
ing issue. Several approaches are available to
treat bleeding in either over-anticoagulation or
proper-anticoagulation, including vitamin K,
fresh frozen plasma and prothrombin complex
concentrates (PCC) administration. In coexist-
ing trauma-induced bleeding and anticoagula-
tion, reversal of anticoagulation must be a
rapid and highly effective procedure.
Furthermore the appropriate treatment must
be directly available in each shock rooms to
guarantee the rapid management of the emer-
gency. PCC require a simple storage, rapid
accessibility, fast administration procedures
and high effectiveness. Here we report the
utility of PCC in management of a craniofacial
trauma in proper-anticoagulation.
Introduction
Life-threatening bleeding in over-anticoagu-
lation or proper-anticoagulation with Warfarin
is an emergency challenging issue. Several
patients require chronic administration of anti-
coagulant therapy rendering them more prone
to spontaneous and trauma-induced bleeding.1,2
Strategies for treatment or prophylaxis of vita-
min K over-anticoagulation include withholding
the vitamin K antagonist, administration of
vitamin K itself, replacement the deficient fac-
tor with prothrombin complex concentrates
(PCC) or fresh-frozen plasma (FFP) and, even if
controversial, by using recombinant Factor VII.
PCC contain vitamin-K dependent clotting fac-
tors (coagulation factor II, factor IX, factor X and
factor VII). The choice of the appropriate treat-
ment relies on the levels of over-anticoagulation
and on the eventual bleeding, as reported in
several guidelines.3-6 In the case of trauma and
over-anticoagulation, treatment is generally an
emergency procedure and therefore the choice
should be focused on an easily accessible drug
able to induce a rapid reversal of anti-coagula-
tion. Although effective in re-coagulation, FFP
requires compatibility testing and carries the
risk of blood borne infection and transfusion-
related acute lung injury. FFP is frozen and
requires at least 20 min to thaw. FFP adminis-
tration is a long procedure therefore being unfit
for the emergency setting. Moreover, faster
accessibility to FFP is available only in those
hospital with a Blood transfusion division.
Finally, the risk associated with large volumes
of FFP infusion cannot be ignored. On the con-
trary, PCC require a simple storage, rapid acces-
sibility and fast administration procedures.
Lastly the volume of solution is dramatically
smaller than in the case of FFP. Currently, there
is little published evidence to support the use of
PCCs in the management of trauma-related
massive bleeding. The results of one retrospec-
tive analysis demonstrated that in trauma
patients receiving warfarin, the addition of PCC
treatment to FFP and vitamin K treatment yield-
ed a more rapid INR reversal; however, no clear
improvement in clinical outcomes was noted.7
Case Report
Here we report a case of an emergency man-
agement of a craniofacial trauma in a anticoag-
ulant treated patient. A 50 years old patient was
admitted to our shock room after a high dynam-
ic impact. Patient was suffering a severe max-
illofacial trauma. The hemodynamic status was
stable and an extendend-FAST-sonography was
negative for pericardia effusion, hemoperi-
toneum and pneumothorax. Accordingly to trau-
ma guidelines, a total body CT scan was there-
fore performed to evaluate internal lesions and
to assess the extension of the craniofacial trau-
ma. No intracranial hemorrhages were
observed. A severe trauma of the zygoma and
the frontal bone with the involvement of orbital
floor was appreciated. Furthermore patient was
suffering lung contusion. Meanwhile the CT
was performed, blood examination showed a
prolonged INR value (2.5) in a patient that we
subsequently discovered to be in anticoagula-
tion for a thrombophylic status. Accordingly to
the high risk of bleeding extension inside the
orbits, with a potential damage of the optical
nerves and a consequent visual defect, PCC
(Uman Complex, Kedrion, Lucca, Italy) were
therefore rapidly administrated accordingly to
standard dosage during the first hour of evalua-
tion of the patient in the emergency depart-
ment. At the end of the procedure, INR was set
at a normal value. In the following hours patient
was evaluated by a maxilla-facial surgeon for
the specific treatment of the fracture. Non visu-
al defect were ever occurred due to the trauma
and hemorrhage. 
Discussion and Conclusions
This case is an example of real-life emer-
gency management of trauma induced bleed-
ing in an anticoagulant treated patient. Patient
needed to be rapidly re-coagulated in order to
prevent visual defects before any potential sur-
gical treatments. PCC represented the best
treatment option because it could be adminis-
trated to the patients in an immediate time-
frame. FFP administration would have
required a much longer time due to the need to
determinate blood group, thaw and adminis-
tration of a large volume of plasma. FFP is also
generally available in a rapid manner only in
those hospital where a transfusion division is
available. Our experience strongly suggests
that PCC are the standard therapy for bleeding
in anticoagulant patient and elevate PCC as
common drug in each shock room. 
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